Falcon's Beyond Global, Inc. Class A Common Stock
FBYDFalcon's Beyond Global, Inc. Class A (FBYD) is a company engaged in the development, licensing, and storytelling of immersive entertainment experiences. It focuses on creating themed attractions, intellectual properties, and branded entertainment ventures aimed at global markets. The company emphasizes innovation in entertainment design and storytelling, seeking to blend technology and creativity to deliver engaging experiences.
Company News
Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares climbed 169% to $1.56Â after the company announced it selected a lead Alzheimer's drug candidate following proof-of-concept study data. LianBio (NASDAQ: LIAN) shares climbed 94.3% to $2.7003 after the company entered into agreement with Bristol Myers Squibb for Mavacamten in China and other...
Gainers INVO Bioscience, Inc. (NASDAQ: INVO) jumped 375% to $2.57 as the company agreed to acquire NAYA Biosciences in an all-stock transaction. LumiraDx Limited (NASDAQ: LMDX) shares climbed 187.4% to $0.25 after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set up England’s first community-ba...
Gainers Nxu, Inc. (NASDAQ: NXU) shares surged 56.4% to $0.1079 in pre-market trading. On Oct. 17, Nxu received formal notice from Nasdaq staff that hearing is scheduled to be held on Dec. 14, 2023. Zapp Electric Vehicles Group Limited (NASDAQ: ZAPP) shares rose 45.1% to $0.7981 in pre-market trading after gaining around 7% on Wednesday. SeaStar...
Gainers Shift Technologies, Inc. (NASDAQ: SFT) shares climbed 107.8% to $0.2239. Shift Technologies recently said it will file for Chapter 11 bankruptcy protection. Treasure Global Inc. (NASDAQ: TGL) climbed 65.1% to $0.5150 after the company announced an AI robot designed to conduct extended-hour live commerce sessions on TikTok. SeaStar Medi...
Gainers Tempest Therapeutics, Inc. (NASDAQ: TPST) shares jumped 1067% to $2.80 after the company released new data demonstrating superiority of TPST-1120 arm across multiple study endpoints in first-line hepatocellular carcinoma study. Phio Pharmaceuticals Corp. (NASDAQ: PHIO) jumped 59.5% to $2.17. Phio Pharmaceuticals presented new data for ta...
